SEEL vs. ZVSA, SNGX, EVOK, ENSC, PTPI, GOVX, CYCC, ALZN, XCUR, and BCEL
Should you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include ZyVersa Therapeutics (ZVSA), Soligenix (SNGX), Evoke Pharma (EVOK), Ensysce Biosciences (ENSC), Petros Pharmaceuticals (PTPI), GeoVax Labs (GOVX), Cyclacel Pharmaceuticals (CYCC), Alzamend Neuro (ALZN), Exicure (XCUR), and Atreca (BCEL). These companies are all part of the "pharmaceutical preparations" industry.
ZyVersa Therapeutics (NASDAQ:ZVSA) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations.
Seelos Therapeutics has higher revenue and earnings than ZyVersa Therapeutics.
ZyVersa Therapeutics currently has a consensus target price of $120.00, indicating a potential upside of 2,690.70%. Seelos Therapeutics has a consensus target price of $360.00, indicating a potential upside of 21,985.89%. Given ZyVersa Therapeutics' higher probable upside, analysts clearly believe Seelos Therapeutics is more favorable than ZyVersa Therapeutics.
ZyVersa Therapeutics has a net margin of 0.00% compared to ZyVersa Therapeutics' net margin of -1,373.61%. ZyVersa Therapeutics' return on equity of 0.00% beat Seelos Therapeutics' return on equity.
In the previous week, Seelos Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 5 mentions for Seelos Therapeutics and 4 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.01 beat Seelos Therapeutics' score of -0.78 indicating that Seelos Therapeutics is being referred to more favorably in the news media.
Seelos Therapeutics received 68 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 66.36% of users gave Seelos Therapeutics an outperform vote.
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are owned by institutional investors. 0.7% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 5.4% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
ZyVersa Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.
Summary
Seelos Therapeutics beats ZyVersa Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Seelos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SEEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seelos Therapeutics Competitors List
Related Companies and Tools
